Author

Andreas Stallmach

Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers
Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers

Andreas Stallmach

Clinical Advances of Infliximab in IBD treatment: Infliximab SC (Celltrion Healthcare)
Clinical Advances of Infliximab in IBD treatment: Infliximab SC (Celltrion Healthcare)

Andreas Stallmach  et al.

REAL-WORLD DATA IN INFLAMMATORY BOWEL DISEASES ON VEDOLIZUMAB THERAPY: INTERIM ANALYSIS OF THE NON-INTERVENTIONAL LISTEN II STUDY
REAL-WORLD DATA IN INFLAMMATORY BOWEL DISEASES ON VEDOLIZUMAB THERAPY: INTERIM ANALYSIS OF THE NON-INTERVENTIONAL LISTEN II STUDY

Andreas Stallmach  et al.

IDENTIFICATION OF RELEVANT PATIENT REPORTED OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - LISTEN I
IDENTIFICATION OF RELEVANT PATIENT REPORTED OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - LISTEN I

Andreas Stallmach  et al.

Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)
Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)

Andreas Stallmach  et al.

Item 1 - 5 / 5
1